Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients
Status:
Unknown status
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn whether oral Ribavirin is safe and effective in
treating patients with solid tumour cancers, that have high levels of the protein eIF4E.